ANXA2 and nasopharyngeal carcinoma: Recently, Chen et al. [33] found absence of ANXA2 significantly increased chemosensitivity of cisplatin/5-FU/docetaxel/vincristine in nasopharyngeal carcinoma cell lines in vitro.